Defunct Company
Total Trials
7
As Lead Sponsor
6
As Collaborator
1
Total Enrollment
170
NCT00393809
Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer
Phase: Phase 1/2
Role: Collaborator
Start: Jan 31, 2006
Completion: Dec 31, 2007
NCT00595088
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
Phase: Phase 2
Role: Lead Sponsor
Start: Jan 31, 2008
Completion: Jan 31, 2013
NCT00826150
Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer
Start: Jun 30, 2009
Completion: Feb 29, 2012
NCT00711997
Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer
Start: Aug 31, 2009
Completion: Dec 31, 2010
NCT01413087
Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma
Start: Sep 30, 2011
Completion: May 31, 2014
NCT01878188
Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma
Phase: Phase 1
Start: Feb 28, 2013
Completion: Oct 31, 2017
NCT03719300
Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
Start: Mar 20, 2019
Completion: Dec 18, 2019